Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 31c

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q3 EPS of ($0.25), $0.31 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $126.17 million versus the consensus estimate of $119.72 million.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• Trump discloses over $1.4 billion in crypto income in 2025 filing
• General Mills (GIS) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 EPS Guidance
• Innovex closes $95M acquisition of TCO Group AS